Targeted

CancerSELECT 125

CancerSELECT 125 analyzes the regions of a targeted panel of 125 well-characterized cancer genes. Matched tumor/normal or tumor samples are prepared using proprietary methods that accommodate low abundance, poor quality sample DNA. Combined with a proprietary capture design and high coverage next-generation sequencing, tumor-specific (somatic) mutations, copy number variations, microsatellite instability (MSI) and translocations are identified with a high sensitivity and specificity.

CancerSELECT 125 Sequencing Key Metrics
Regions AnalyzedCoding regions of 117 genes and selected regions of 41 genes
Sequencing MethodIllumina next generation sequencing
BioinformaticsPatented PARE, Digital Karyotyping
and VariantDx
Assay Sensitivity>99%
Assay Specificity>99.9999%
Sequencing Coverage1,250x
Turn-around Time2-3 weeks
Sample RequirementsTumor only or tumor and matched normal (optimal results)
Sample TypesFrozen tumor or FFPE, cell lines, blood, saliva, and xenograft
DNA Input Required1μg (minimum 50ng)
Exome

CancerCOMPLETE®

CancerCOMPLETE® utilizes exome capture to selectively analyze only the coding regions of the genome, allowing the coding regions, the “exome,” to be sequenced at high coverage. Using the tumor tissue and matched normal sample, this allows for the reliable identification of sequence mutations and copy number alterations. Additionally, regions frequently mutated in cancer (88 genes included in the CancerCOMPLETE® tests) are analyzed at high coverage to identify point mutations, copy number alterations, rearrangements and microsatellite instability (MSI).

CancerCOMPLETE® Key Metrics
Regions AnalyzedCoding regions of >20,000 genes and selected regions of 24 genes
Sequencing MethodIllumina next generation sequencing
BioinformaticsProprietary methods and visual inspection
Assay Sensitivity>95%
Assay Sensitivity>99.99%
Sequencing Coverage150x
Turn-around Time6 weeks (rush available)
Sample RequirementsMatched tumor and normal specimens (Blood or saliva)
Sample TypesFrozen tumor, FFPE, cell lines,
blood, saliva, and xenograft
DNA Input Required1 µg (minimum 50 ng)
Minimum Tumor Cellularity>70%
Multi-Gene

PlasmaSELECT™

PlasmaSELECT™ analyzes circulating tumor DNA for genetic alterations in cancer, eliminating the need for an invasive biopsy or tumor tissue. PlasmaSELECT™ may also be used to evaluate subclonal mutations in tumor tissue, when available. PlasmaSELECT™ evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations, rearrangements or microsatellite instability (MSI) can be performed together or separately, depending on the specific alterations of interest.

PlasmaSELECT™ Key Metrics
Regions Analyzed64 Genes
Sequencing MethodIllumina next-generation sequencing
BioinformaticsPatented PARE, Digital Karyotyping and VariantDx
Turn-around Time2-3 weeks
Sample RequirementsWhole blood or plasma
Sample Input RequiredTwo 10 ml tubes of peripheral whole blood; 6-10 ml plasma collected according to PGDx sample preparation instructions (>1-2ml for RUO)